Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing‐remitting multiple sclerosis-Reference-Cited by-同舟云学术

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing‐remitting multiple sclerosis

Published:2011-01-17 Issue:2 Volume:18 Page:240-245
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:European Journal of Neurology

Author:

Belachew S.¹²,Phan‐Ba R.¹²,Bartholomé E.¹³,Delvaux V.¹²,Hansen I.¹²,Calay P.¹²,Hafsi K. E.¹⁴,Moonen G.²,Tshibanda L.⁵,Vokaer M.¹⁴

Affiliation:

1. MYelin Disorders REseArch teaM (MYDREAM)

2. Department of Neurology, C.H.U. Liège University Hospital, Liège

3. Department of Neurology, C.H.U. Tivoli, La Louvière

4. Department of Neurology, Erasme University Hospital, Brussels

5. Department of Neuroradiology, C.H.U. Liège University Hospital, Liège, Belgium

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1468-1331.2010.03112.x

Reference18 articles.

1. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

3. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries

4. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

5. Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in Switzerland

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the ‘suboptimal therapy’ patient population;Journal of the Neurological Sciences;2024-09

2. Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod;Journal of Neurology;2024-08-23

3. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis;JAMA Neurology;2023-07-01

4. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis;Multiple Sclerosis and Related Disorders;2023-04

5. The interplay between T helper cells and brain barriers in the pathogenesis of multiple sclerosis;Frontiers in Cellular Neuroscience;2023-02-15